Background: Selectively increased radioiodine accumulation in thyroid cells by thyrotropin
4 4 treatment with inhibitors. In this experimental setting, we show that Akt inhibitor (Akti1/2) had the greatest extent of increase in RAIU and Apigenin further increased thyroidal RAIU in combination with Akti1/2. The action of Apigenin to further increase Akti1/2-induced RAIU in thyroid cells is dependent on p38 MAPK activity. Taken together, Apigenin has the potential to serve as a dietary supplement along with Akt inhibitors to increase the efficacy of radioiodine therapy for patients with advanced thyroid cancer.
Methods:
Cell culture, reagents and TRβ PV/PV mouse model. PCCl3 rat thyroid cells were maintained in 6H media with 5% bovine serum as described by Liu et al. (5), unless specified otherwise.
Experiments were performed under acute TSH stimulation, where cells were withdrawn from TSH for 5 days (5H media) and then TSH was added back for 24 hrs prior to treatment with various reagents for additional 24 hrs, unless specified otherwise. PCCl3/TetOn-BRAF V600E , a generous gift from Dr. James Fagin, Memorial Sloan Kettering Cancer Center, New York (10) and PCCl3/TetOn-PTC1 cells (4) were genetically modified from PCCl3 cells to allow doxycycline-inducible expression of BRAF V600E or PTC1 oncogenes respectively. Experiments were performed under acute TSH stimulation with or without 2 µg/ml of doxycycline for 48 hrs, followed by treatment with reagents for additional 24 hrs. Primary cultured cells from mouse thyroid tumors were isolated using a tumor dissociation kit (Miltenyi Biotec Inc., Bergisch Gladbach, Germany), according to the manufacturer's protocol and were cultured in 6H media.
Reagents used in this study are listed as follows: Akti1/2 also known as Akt inhibitor VIII, 17- This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
RT 2 profiler PCR array and Ingenuity Pathway Analysis (IPA). A Rat Epithelial to
Mesenchymal transition (EMT) RT 2 Profiler PCR array that profiles the expression of 84 key genes was purchased from SABiosciences, Valencia, CA. Total RNA isolated from PCCl3 cells treated with DMSO, Akti1/2, and TGF-β was reversed transcribed to cDNA and real-time PCR was performed per manufacturer's instructions. Genes with expression levels of Ct value less than 30 in either the experimental or the control group along with their fold changes were submitted for IPA analysis to predict upstream transcription factors and their activation status.
Additional downstream targets of these transcription factors were identified by IPA analysis.
Among targets identified, we searched for ones that are oppositely modulated by Akti1/2 and TGF-β.
Transfections. Plasmid transfections were conducted using FuGENE®6 (Promega, Madison, WI) for 24 hrs followed by replacement with fresh media for 24 hrs. Stably transfected cells were selected under media containing 800 µg/ml of G418 (Life Technologies, Carlsbad, CA) for 2 weeks with media replacement every other day. Mixed stable clones were then maintained in 400 µg/ml of G418. Transfections with siRNAs were facilitated by incubating with This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Akt inhibition decreases . Taken together, Akti1/2 and TGF-β modulate both RAIU and EMT in an opposite manner. We thus hypothesized that EMT-associated genes may modulate RAIU in thyroid cells. We examined expression levels of 84 EMT-associated genes using EMT PCR array in cells treated with DMSO, Akti1/2 or TGF-β. The results were subjected to IPA analysis, and involucrin, a transglutaminase substrate protein, was predicted to be downregulated by Akti1/2 yet upregulated by TGF-β. Since involucrin expression appears to be inversely correlated with RAIU, we speculated that Apigenin, a plant-derived flavonoid known to inhibit involucrin expression in keratinocytes, may further increase Akti1/2-induced RAIU. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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Apigenin further increases RAIU in Akti1/2-treated PCCl3 cells.
Apigenin ( This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
10 combination with Akt inhibition. As expected, Apigenin further increased RAIU in PCCl3-shAkt1/2 cells, yet had little effect on RAIU in PCCl3-vector control cells.
It has been shown that phospho-Akt level is decreased in the absence of insulin in FRTL-5 rat thyroid cells under low-serum culture media (30). To recapitulate this culture condition, PCCl3 cells were deprived of TSH and insulin (4H) with 0.2% serum for 5 days, and then 4H culture media was replaced with 4H+TSH or 6H (4H+TSH+insulin) culture media for 24 hrs before adding either DMSO vehicle or Apigenin for an additional 24 hrs. As shown in Figure   3C , Apigenin did not increase RAIU in cells cultured in 4H or 6H condition, yet it did further increase RAIU in cells with 4H+TSH culture media. Note that phospho-Akt level in cells with 4H+TSH was lower than that in cells with 4H or 6H culture media ( Figure 3D ). Apigenin suppressed phospho-Akt levels in all three experimental groups and the extent of suppression is more pronounced in 0.2% serum than 5% serum conditions ( Figure 3D vs. Figure 2B ).
Since TSH is required for NIS expression, protein stability, and function, NIS protein is absent in cells under 4H conditions. Accordingly, Apigenin was not able to induce RAIU in the absence of TSH. The inability of Apigenin to increase RAIU under 6H conditions may be attributed to other effects of insulin rather than a higher phospho-Akt level prior to Apigenin addition. Taken together, Akt inhibition appears to be permissive for Apigenin to further increase RAIU, yet Apigenin's action to further enhance RAIU does not correlate with its effect on suppressing phospho-Akt levels.
Apigenin further increases iodide influx rate in Akti1/2-treated PCCl3 cells. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Since iodide uptake is mediated by NIS protein localized on the cell surface, we examined if Apigenin increases cell surface NIS protein levels in Akti1/2-treated PCCl3 cells. As shown in Figure 4A , Apigenin did not increase total or cell surface NIS protein levels in Akti1/2-treated cells. The absence of β-actin in cell surface fractions confirms the absence of cytosolic proteins.
Because RAIU activity represents a steady state equilibrium between iodide influx and iodide efflux, we investigated whether Apigenin decreases iodide efflux rate in Akti1/2-treated cells. As shown in Figure 4B , Apigenin had little effect on the iodide efflux rate, which is different from the mechanism of 17-AAG (4). Figure 5C and Figure 5D ). Using siRNA to knockdown either each individual or all four isoforms, p38MAPK was knocked down up to 60%
and this was not sufficient to decrease p38 MAPK activity. Accordingly, neither increase in nonphosphorylated form of MAPKAPK2, nor decrease in RAIU, was observed (data not shown).
Apigenin's action to increase RAIU in Akti1/2-treated cells is independent of PKC-δ.
Another well-known downstream effector of Apigenin is PKC-δ (32, 33). To test if
Apigenin modulates RAIU via PKC-δ, genetic knockdown of PKC-δ was performed using siRNAs. As shown in Figure 6A , neither RAIU in cells of all experimental groups, nor the This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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16 cells with 0.2% serum culture media. Furthermore, SB203580 diminished Apigenin's effect to further increase RAIU in Akti1/2 treated cells without evident change in phospho-Akt levels.
Finally, it is of interest to note that an increase of M r in NIS only occurred in cells treated with Apigenin+Akt inhibition. This suggests that Apigenin's action to further increase RAIU in Akti1/2 treated cells may not be fully explained by its effect on further Akt inhibition.
SB203580 decreased TSH-induced NIS mRNA levels, when SB203580 and TSH were added at the same time to TSH-deprived FRTL-5 cells (42, 43) . In this study, a p38 MAPK inhibitor was added 24 hrs after acute TSH stimulation, when NIS mRNA and protein were already synthesized. Neither SB203580 nor BIRB-796 altered steady state NIS protein levels, yet both resulted in drastic decrease in RAIU. Accordingly, p38 MAPK activity is not only required for TSH-stimulated NIS expression but also required for optimal NIS-mediated RAIU activity.
However, the action of Akti1/2 on RAIU is independent of p38 MAPK activity, as neither SB203580 nor BIRB-796 affected the fold of increase in RAIU by Akti1/2 alone.
Matowe et al. reported that PKC-δ disappeared within 24 hrs of TSH withdrawal and reappeared 24 hrs after TSH addition in FRTL-5 rat thyroid cells (44). Our study shows that steady state NIS protein levels were modestly decreased upon PKC-δ knockdown, yet without accompanied change in RAIU. This discrepancy may be explained by an absent change in cell surface NIS protein levels or by an increased NIS activity that compensates the decreased NIS protein levels. Neither Akti1/2-induced RAIU nor Apigenin's ability to further increase Akti1/2-induced RAIU was dependent upon PKC-δ. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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The increase in RAIU by Apigenin+Akti1/2 was reproduced in BRAF V600E or RET/PTC1 expressing thyroid cells. Apigenin+Akti1/2 also increased RAIU in thyroid tumor cells from This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. In panels (B) and (D), GAPDH served as a loading control. Arrows  and <--indicate This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
